Clinical Trial Update: A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating letermovir (Prevymis) for preventing recurrent cytomegalovirus infection in hematopoietic cell transplant recipients has completed, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• PREVYMIS (letermovir)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: CMV, CMV Infection | Phase 2 | Status: COMPLETED | Results posted: 2025-07-30